In the medically managed cohort , 2-year primary outcome ( cardiovascular death , myocardial infarction , stroke , recurrent ischaemia with rehospitalization , urgent coronary revascularization ) event rates were 16.3 % with vorapaxar and 17.0 % with placebo ( HR 0.99 , 95 % CI 0.83-1 .17 ) , with no interaction between drug and management strategy ( p = 0.75 ) .